CA2283797A1
(en)
*
|
1997-03-18 |
1998-09-24 |
Paul Elliot Bender |
Novel cannabinoid receptor agonists
|
JP2002512188A
(ja)
|
1998-04-21 |
2002-04-23 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗酸化剤及び神経保護剤としてのカンナビノイド類
|
DE69910373T2
(de)
*
|
1998-05-04 |
2004-04-01 |
The University Of Connecticut, Farmington |
Analgetische und immunomodulierende cannabinoiden
|
US7589220B2
(en)
*
|
1998-06-09 |
2009-09-15 |
University Of Connecticut |
Inhibitors of the anandamide transporter
|
US7897598B2
(en)
*
|
1998-06-09 |
2011-03-01 |
Alexandros Makriyannis |
Inhibitors of the anandamide transporter
|
US7161016B1
(en)
|
1998-11-24 |
2007-01-09 |
University Of Connecticut |
Cannabimimetic lipid amides as useful medications
|
US7276613B1
(en)
|
1998-11-24 |
2007-10-02 |
University Of Connecticut |
Retro-anandamides, high affinity and stability cannabinoid receptor ligands
|
FR2789079B3
(fr)
*
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
US6900236B1
(en)
*
|
1999-10-18 |
2005-05-31 |
University Of Connecticut |
Cannabimimetic indole derivatives
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
US7741365B2
(en)
*
|
1999-10-18 |
2010-06-22 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
AU778159B2
(en)
|
1999-10-18 |
2004-11-18 |
University Of Connecticut, The |
Peripheral cannabinoid receptor (CB2) selective ligands
|
US8084467B2
(en)
*
|
1999-10-18 |
2011-12-27 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US6943266B1
(en)
|
1999-10-18 |
2005-09-13 |
University Of Connecticut |
Bicyclic cannabinoid agonists for the cannabinoid receptor
|
US7119108B1
(en)
|
1999-10-18 |
2006-10-10 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
FR2800375B1
(fr)
|
1999-11-03 |
2004-07-23 |
Sanofi Synthelabo |
Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
|
JP2003534298A
(ja)
*
|
2000-05-23 |
2003-11-18 |
ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア |
咳の新規治療法
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
US8449908B2
(en)
*
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
EP1361876A4
(de)
*
|
2001-01-26 |
2004-03-31 |
Univ Connecticut |
Neue cannabimimetische liganden
|
EP1363632B1
(de)
|
2001-01-29 |
2010-08-25 |
The University of Connecticut |
Rezeptor-selektive cannabimimetische aminoalkylindole
|
US7057076B2
(en)
*
|
2001-07-13 |
2006-06-06 |
University Of Connecticut |
Bicyclic and tricyclic cannabinoids
|
AU2002319627A1
(en)
*
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
JP2005510492A
(ja)
*
|
2001-10-26 |
2005-04-21 |
ユニバーシティ オブ コネチカット |
新規な種類の効力のあるカンナビミメティックリガンド
|
AU2003209388A1
(en)
*
|
2002-01-29 |
2003-09-02 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
EP1487436A4
(de)
|
2002-03-08 |
2009-06-03 |
Signal Pharm Inc |
Kombinationstherapie zur behandlung, prävention oder versorgung von proliferativen erkrankungen und krebs
|
EP1496838B1
(de)
*
|
2002-03-12 |
2010-11-03 |
Merck Sharp & Dohme Corp. |
Substituierte amide
|
WO2003082190A2
(en)
*
|
2002-03-26 |
2003-10-09 |
Merck & Co., Inc. |
Spirocyclic amides as cannabinoid receptor modulators
|
JP2005531520A
(ja)
*
|
2002-03-28 |
2005-10-20 |
メルク エンド カムパニー インコーポレーテッド |
置換2,3−ジフェニルピリジン類
|
CA2480856A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Merck & Co., Inc. |
Substituted aryl amides
|
EP1499306A4
(de)
*
|
2002-04-12 |
2007-03-28 |
Merck & Co Inc |
Bicyclische amide
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
AU2003250117B2
(en)
|
2002-07-29 |
2007-05-10 |
F. Hoffmann-La Roche Ag |
Novel benzodioxoles
|
JP4667867B2
(ja)
*
|
2002-08-02 |
2011-04-13 |
メルク・シャープ・エンド・ドーム・コーポレイション |
置換フロ[2,3−b]ピリジン誘導体
|
AU2003265663A1
(en)
|
2002-08-23 |
2004-03-11 |
University Of Connecticut |
Keto cannabinoids with therapeutic indications
|
AR041268A1
(es)
*
|
2002-09-19 |
2005-05-11 |
Solvay Pharm Bv |
Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
SE0203070D0
(en)
|
2002-10-16 |
2002-10-16 |
Astrazeneca Ab |
Novel compounds
|
JP2006506366A
(ja)
*
|
2002-10-18 |
2006-02-23 |
ファイザー・プロダクツ・インク |
カンナビノイド受容体リガンドおよびその使用方法
|
ITMI20022228A1
(it)
*
|
2002-10-21 |
2004-04-22 |
Dinamite Dipharma S P A |
Sali di clopidogrel con acidi alchil-solforici.
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
MXPA05007114A
(es)
|
2003-01-02 |
2005-08-26 |
Hoffmann La Roche |
Nuevos agonistas inversos del receptor cb1.
|
MXPA05007115A
(es)
|
2003-01-02 |
2005-11-16 |
Hoffmann La Roche |
Nuevos agonistas inversos del receptor cb 1.
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
RU2344132C2
(ru)
|
2003-06-20 |
2009-01-20 |
Ф.Хоффманн-Ля Рош Аг |
2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1
|
FR2856683A1
(fr)
*
|
2003-06-25 |
2004-12-31 |
Sanofi Synthelabo |
Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
|
FR2856684B1
(fr)
*
|
2003-06-26 |
2008-04-11 |
Sanofi Synthelabo |
Derives de diphenylpyridine, leur preparation et leur application en therapeutique
|
US7754188B2
(en)
*
|
2003-06-30 |
2010-07-13 |
Merck Sharp & Dohme Corp. |
Radiolabeled cannabinoid-1 receptor modulators
|
US20050026983A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Pfizer Inc |
Imidazole compounds and uses thereof
|
JP4765627B2
(ja)
|
2003-09-22 |
2011-09-07 |
Msd株式会社 |
新規ピペリジン誘導体
|
WO2005058887A1
(en)
|
2003-12-08 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Novel thiazole derivates
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
ES2349195T3
(es)
|
2004-01-28 |
2010-12-28 |
F. Hoffmann-La Roche Ag |
Espiro-benzodioxoles y su uso como antagonistas de cb1.
|
US20080255216A1
(en)
|
2004-03-29 |
2008-10-16 |
Aster Susan D |
Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
ES2324720T3
(es)
|
2004-05-10 |
2009-08-13 |
F. Hoffmann-La Roche Ag |
Pirrol o imidazol amidas para tratar la obesidad.
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
AU2005278781B2
(en)
|
2004-07-12 |
2009-06-18 |
Cadila Healthcare Limited |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
CA2575736A1
(en)
|
2004-08-06 |
2006-02-16 |
Merck & Co., Inc. |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
FR2874012B1
(fr)
*
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
CA2577060A1
(en)
*
|
2004-08-13 |
2006-02-23 |
Amgen Inc. |
Substituted benzofused heterocycles
|
WO2006039334A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
CN101048382B
(zh)
|
2004-10-27 |
2010-05-05 |
霍夫曼-拉罗奇有限公司 |
新型吲哚或苯并咪唑衍生物
|
US20090156474A1
(en)
|
2004-11-01 |
2009-06-18 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1812418B1
(de)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Dibenzosuberon-derivate
|
JP2008525404A
(ja)
*
|
2004-12-23 |
2008-07-17 |
アストラゼネカ アクチボラグ |
治療剤
|
US20080319019A1
(en)
*
|
2004-12-23 |
2008-12-25 |
Leifeng Cheng |
Therapeutic Agents
|
JP2008526887A
(ja)
*
|
2005-01-10 |
2008-07-24 |
ユニバーシティ オブ コネチカット |
カンナビノイド受容体に作用する新規なヘテロピロール類似体
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
BRPI0609685A2
(pt)
*
|
2005-04-06 |
2010-04-20 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US20060278280A1
(en)
*
|
2005-05-23 |
2006-12-14 |
Tzai-Jen Yang |
Check valve
|
EP1890767A2
(de)
*
|
2005-05-27 |
2008-02-27 |
Pfizer Products Inc. |
Kombinationstherapie zur behandlung von fettleibigkeit oder aufrechterhaltung des gewichtverlusts
|
AU2006253312B2
(en)
|
2005-05-30 |
2011-08-18 |
Msd K.K. |
Novel piperidine derivative
|
US7923465B2
(en)
*
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
ES2353818T3
(es)
*
|
2005-06-22 |
2011-03-07 |
F. Hoffmann-La Roche Ag |
(6-fluor-benzo[1,3]dioxolil)-morfolin-4-il-metanonas y su uso como ligandos de cb1.
|
CA2518579A1
(en)
*
|
2005-08-05 |
2007-02-05 |
University Technologies International Inc. |
Method for appetite suppression
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
EP2330124B1
(de)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybridpolypeptide mit auswählbaren Eigenschaften
|
EP2330125A3
(de)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybridpolypeptide mit auswählbaren Eigenschaften
|
CA2619770A1
(en)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
AU2006312557B2
(en)
|
2005-11-10 |
2011-12-08 |
Msd K.K. |
Aza-substituted spiro derivative
|
EP1801098A1
(de)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
|
AU2007226673A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7781593B2
(en)
*
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
EP2083831B1
(de)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Verfahren zur behandlung von fettsäure-synthese-hemmern
|
CA2664358A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diarylketimine derivative
|
US20080108643A1
(en)
*
|
2006-11-03 |
2008-05-08 |
Forest Laboratories Holdings Limited |
Method for treating autism
|
EP2121617B1
(de)
|
2006-12-18 |
2014-01-22 |
7TM Pharma A/S |
Cb1-rezeptormodulatoren
|
EP1935420A1
(de)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
|
EP2145884B1
(de)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledionderivat
|
PE20090142A1
(es)
*
|
2007-04-11 |
2009-02-19 |
Merck & Co Inc |
Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
ES2534900T3
(es)
*
|
2007-07-30 |
2015-04-30 |
Zynerba Pharmaceuticals, Inc. |
Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
|
US8133904B2
(en)
*
|
2007-09-07 |
2012-03-13 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
MX2010005345A
(es)
*
|
2007-11-14 |
2010-08-31 |
Amylin Pharmaceuticals Inc |
Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
|
KR20100091255A
(ko)
*
|
2007-12-10 |
2010-08-18 |
7티엠 파마 에이/에스 |
카나비노이드 수용체 조절자
|
WO2009099670A2
(en)
*
|
2008-02-08 |
2009-08-13 |
Nektar Therapeutics Al, Corporation |
Oligomer-cannabinoid conjugates
|
US20090247619A1
(en)
*
|
2008-03-06 |
2009-10-01 |
University Of Kentucky |
Cannabinoid-Containing Compositions and Methods for Their Use
|
JPWO2009110510A1
(ja)
|
2008-03-06 |
2011-07-14 |
Msd株式会社 |
アルキルアミノピリジン誘導体
|
JPWO2009119726A1
(ja)
|
2008-03-28 |
2011-07-28 |
Msd株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
EP2110374A1
(de)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
|
US20110071129A1
(en)
|
2008-06-19 |
2011-03-24 |
Makoto Ando |
Spirodiamine-diaryl ketoxime derivative
|
EP2321341B1
(de)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
WO2010013595A1
(ja)
|
2008-07-30 |
2010-02-04 |
萬有製薬株式会社 |
5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
|
IT1390848B1
(it)
|
2008-07-31 |
2011-10-19 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
EP2149370A1
(de)
|
2008-07-31 |
2010-02-03 |
Neuroscienze Pharmaness S.C. A R.L. |
Diazabizyclischen Verbindungen und Mikroemulsionen, dieselben enthaltend
|
EP2348857B1
(de)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Neue cyclische benzimidazolderivate als antidiabetika
|
EP2350010B1
(de)
|
2008-10-30 |
2014-03-26 |
Merck Sharp & Dohme Corp. |
Isonikotinamide als orexinrezeptorantagonisten
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EP2358200A4
(de)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
Substituierte bizyklische amine für die behandlung von diabetes
|
EP2379562A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclische pyranonderivate als agonisten am nicotinsäurerezeptor
|
EP2379547A1
(de)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidinderivate und verfahren zu deren anwendung
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
IT1394400B1
(it)
*
|
2009-02-25 |
2012-06-15 |
Neuroscienze Pharmaness S C Ar L |
Composizioni farmaceutiche
|
IT1395724B1
(it)
|
2009-02-25 |
2012-10-19 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
IT1394860B1
(it)
|
2009-07-22 |
2012-07-20 |
Kemotech S R L |
Composti farmaceutici
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
DE102009035649A1
(de)
*
|
2009-07-29 |
2011-02-03 |
Siemens Aktiengesellschaft |
Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes
|
US8765728B2
(en)
|
2009-11-16 |
2014-07-01 |
Mellitech |
[1,5]-diazocin derivatives
|
IT1396951B1
(it)
*
|
2009-12-18 |
2012-12-20 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
JP5540454B2
(ja)
*
|
2009-12-30 |
2014-07-02 |
シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド |
ジペプチジルペプチダーゼ阻害剤
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
EP2563764B1
(de)
|
2010-04-26 |
2015-02-25 |
Merck Sharp & Dohme Corp. |
Neue spiropiperidin-prolylcarboxypeptidase-hemmer
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
EP2579873A4
(de)
|
2010-06-11 |
2013-11-27 |
Merck Sharp & Dohme |
Neuartige prolylcarboxypeptidase-hemmer
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
MX348131B
(es)
|
2011-02-25 |
2017-05-26 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
|
WO2013048989A2
(en)
|
2011-09-30 |
2013-04-04 |
National Health Research Institutes |
Pyrazole compounds
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
US20140045746A1
(en)
|
2012-08-02 |
2014-02-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US9840512B2
(en)
|
2013-02-22 |
2017-12-12 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonisten der guanylatcyclase und deren verwendungen
|
EP2789619A1
(de)
|
2013-04-12 |
2014-10-15 |
Kemotech S.r.l. |
Pharmazeutische Verbindungen mit angiogenesehemmender Wirkung
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
BR112016028119A2
(pt)
|
2014-06-06 |
2017-08-22 |
Res Triangle Inst |
Agonistas receptores de apelina (apj) e usos dos mesmos
|
ES2901114T3
(es)
|
2014-08-29 |
2022-03-21 |
Tes Pharma S R L |
Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
|
EP3386976A1
(de)
|
2015-12-09 |
2018-10-17 |
Research Triangle Institute, International |
Verbesserte apelinrezeptor (apj)-agonisten und verwendungen davon
|
KR20190065312A
(ko)
|
2016-10-14 |
2019-06-11 |
테스 파마 에스.알.엘. |
알파-아미노-베타-카복시뮤콘산 세미알데하이드 데카복실라제의 저해제
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
WO2020104456A1
(en)
|
2018-11-20 |
2020-05-28 |
Tes Pharma S.R.L |
INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
WO2022040070A1
(en)
|
2020-08-18 |
2022-02-24 |
Merck Sharp & Dohme Corp. |
Bicycloheptane pyrrolidine orexin receptor agonists
|